Evidence map›Paper›PMID 22964723›Full record

ArticleThe American journal of tropical medicine and hygiene2012

Frequency of reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an episode of severe cholera in a highly endemic area in Bangladesh.

Ana A Weil, Fahima Chowdhury, Ashraful I Khan, Daniel T Leung, Taher Uddin, Yasmin Ara Begum, Nirod Chandra Saha, Richelle C Charles, Regina C Larocque, Jason B Harris and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Long-Term Kinetics of Serological Antibodies againstInternational journal of environmental research and public health · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. The Lancet. Microbe · 2020
    Article
  6. Plasma Leptin Levels in Children Hospitalized with Cholera in Bangladesh.The American journal of tropical medicine and hygiene · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ana A WeilDepartment of Medicine, Harvard Medical School, Boston, MA, USA. aweil@partners.org
Fahima Chowdhury
Ashraful I Khan
Daniel T Leung
Taher Uddin
Yasmin Ara Begum
Nirod Chandra Saha
Richelle C Charles
Regina C Larocque
Jason B Harris
Edward T Ryan
Firdausi Qadri
Stephen B Calderwood
Harvard University Press · USHarvard University · US

Funding

Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
Protecutive immunity to human cholera in BangladeshU01AI058935 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CALDERWOOD, STEPHEN B., RYAN, EDWARD T. · 2003 to 2014
$7.8M
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine developmentU01AI077883 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2008 to 2012
$5.6M
Training program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4M
The role of TcpA in cholera immunity and vaccinationK01TW007409 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B · 2005 to 2011
$867k
High-throughput proteomic study of protective immunity in human cholera infectionK08AI089721 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHARLES, RICHELLE C · 2010 to 2014
$684k
Identification of human gene polymorphisms related to Vibrio cholerae infectionK01TW007144 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI LAROCQUE, REGINA C · 2004 to 2009
$617k
Mucosal immune response to oral cholera vaccine Peru 15R03AI063079 · NIAID · INTERNATIONAL CTR/DIARRHOEAL DIS RES · PI QADRI, FIRDAUSI · 2005 to 2007
$158k
FIC NIH HHS D43 TW005572FIC NIH HHS K01 TW007144FIC NIH HHS K01 TW007409FIC NIH HHS K01 TW07144FIC NIH HHS K01 TW07409FIC NIH HHS R24 TW007988FIC NIH HHS TW005572FIC NIH HHS TW05572Howard Hughes Medical InstituteNIAID NIH HHS AI058935NIAID NIH HHS K08 AI089721NIAID NIH HHS R03 AI063079NIAID NIH HHS U01 AI058935NIAID NIH HHS U01 AI077883
6 · The paper itself

Abstract

Vibriocidal antibody is a marker of recent exposure to Vibrio cholerae O1 infection. We examined vibriocidal titers for 1 year after an episode of severe cholera in patients in Dhaka, Bangladesh; 16 of 53 (30%) patients had a fourfold or greater increase in vibriocidal titer between 6 and 12 months after an episode of severe cholera, suggesting reexposure to the organism. Among patients with rises in titers during follow-up, the patients initially infected with serotype Ogawa had earlier rises in titer than the patients initially infected with serotype Inaba. These data and others suggest that an episode of severe cholera protects against symptomatic disease for several years, but reexposure to the organism occurs frequently in an endemic area, with immunological boosts beginning as early as 6 months after severe disease. Repeated exposures to V. cholerae in endemic areas may be a necessary component for long-lasting protection against severe disease.

Indexed as

AdolescentAdultBangladeshChildCholeraColony Count, MicrobialFemaleHumansMaleMiddle AgedVibrio cholerae

Identifiers

PMID22964723
PMCPMC3516269
OpenAlexW2109885373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.